Axogen, Inc. delivered strong Q3 '25 results, with revenue up 23.7% and a return to profitability, fueling bullish momentum. Surgeon adoption is accelerating ahead of the December 5th FDA decision on Avance Nerve Graft, a pivotal regulatory inflection point. The BLA submission features over a decade of real-world outcomes, robust manufacturing validation, and clinical recovery rates in the low-80% range.
AxoGen (AXGN) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago.
The average of price targets set by Wall Street analysts indicates a potential upside of 76.4% in AxoGen (AXGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
| Health Care Equipment & Supplies Industry | Healthcare Sector | Michael D. Dale CEO | XSTU Exchange | US05463X1063 ISIN |
| US Country | 451 Employees | 12 Feb 2010 Last Dividend | 11 Jul 1994 Last Split | 27 Mar 1990 IPO Date |
AxoGen, Inc., alongside its subsidiaries, plays a pivotal role in advancing the field of peripheral nerve regeneration and repair around the globe. This innovative company is focused on developing and bringing to market specialized technologies that address critical needs in nerve repair. By providing state-of-the-art solutions, AxoGen, Inc. is committed to improving the quality of life for patients suffering from peripheral nerve injuries. The company serves a diverse clientele, including hospitals, surgery centers, military hospitals, as well as plastic reconstructive, orthopedic, and hand surgeons, and oral and maxillofacial surgeons, operating out of its headquarters in Alachua, Florida.
A pioneering product in nerve repair, the Avance Nerve Graft is a biologically active, off-the-shelf processed human nerve allograft designed for bridging severed peripheral nerves. This innovative solution offers a significant advantage by eliminating the comorbidities associated with harvesting grafts from a second surgical site, thereby facilitating a more efficient and less invasive recovery for patients.
This product takes advantage of a porcine submucosa extracellular matrix (ECM) to assist in the tensionless repair of severed peripheral nerves. The AxoGuard Nerve Connector facilitates the precise alignment and connection of nerve endings, promoting optimal healing and nerve function recovery.
As a porcine submucosa ECM product, the AxoGuard Nerve Protector is utilized to wrap and safeguard damaged peripheral nerves. It plays a vital role in nerve reconstruction by reinforcing the repair process while preventing soft tissue attachments, thereby ensuring the integrity and functionality of the nerve post-repair.
This advanced version incorporates a processed porcine submucosa ECM base layer along with a hyaluronate-alginate gel coating. The Axoguard HA+ Nerve Protector is specifically designed to provide both short and long-term protection for peripheral nerve injuries, offering an enhanced barrier and healing environment.
The Axoguard Nerve Cap is crafted from a porcine submucosa ECM and is used to protect the end of a peripheral nerve. It effectively isolates the nerve from the surrounding tissues to minimize the development of symptomatic or painful neuroma, thereby contributing to a better patient outcome.
This specialized tool is employed for measuring the innervation density of the skin's surface area. The AxoTouch Two-Point Discriminator is an essential instrument for assessing the success of nerve repair and recovery, providing valuable feedback for surgeons and patients alike.